Ribociclib Improves Progression-Free Survival for Some Women with Metastatic Breast Cancer
A summary of interim results from a phase III trial testing ribociclib plus letrozole (Femara®) as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Media Type: Html
- SourceUrl: https://www.cancer.gov/node/1066661/syndication
- Syndication ID: 16203
- Language: English
- Source: National Cancer Institute (NCI)
- Date Syndication Captured: Tuesday, November 15, 2016 at 03:31 PM
- Date Syndication Updated: Monday, August 05, 2019 at 07:40 PM
Embed Code Snippet
To get the embed code snippet please Login.
